This site is intended for health professionals only
Newsletter
Hospital Healthcare Europe
Login
Twitter
Linkedin
Facebook
Select Language
English
French
German
Italian
Spanish
News
Views
Reviews & Research
Clinical
Cardiovascular
Dermatology
Gastroenterology
Medicines safety
Mental health
Neurology
Oncology
Paediatrics
Respiratory
Rheumatology
Sponsored
Events
News
Views
Reviews & Research
Clinical
Cardiovascular
Dermatology
Gastroenterology
Medicines safety
Mental health
Neurology
Oncology
Paediatrics
Respiratory
Rheumatology
Sponsored
Events
Home
>
Hepatology
Hepatology
Albireo AB liver drug receives positive opinion
EASL: Telaprevir avoids side-effects in hepatitis
Health economics of protease inhibitors
Prescribing for patients with liver disease
Treatment options for hepatitis C
INCIVO® demonstrates efficacy for hepatitis C
European Commission approves telaprevir for hepatitis C
Role of protease inhibitors in treatment of chronic hepatitis C
Boehringer Ingelheim’s hepatitis C compound moves into phase III
Telaprevir beats HCV standard care
Tibotec releases final results of Phase 3 REALIZE study
Research specialists host R&D day
« Previous
1
2
3
4
5
6
…
9
Next »
Most read
1
Transcranial magnetic stimulation brain connectivity changes in major depression visible on MRI scan
by Rod Tucker
2
Oral vitamin A could become an alternative to isotretinoin for acne
by Rod Tucker
3
Amino acids supplement reduces muscle wasting and improves gut function in critically ill
by Rod Tucker
4
Less than two-thirds of patients alive 10 years after out-of-hospital cardiac arrest
by Rod Tucker
5
Launch of the new Hospital Pharmacy Europe Mobile App
by aporter2
Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Subscribe
x
Search for: